NGLFINE · NSE
NGL Fine-Chem Limited
₹2,768.2
+1.95% (+₹52.9)
Prev. close
₹2,715.3
Volume
11,325
Delivery %
77.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About NGL Fine-Chem Limited
NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxacin, maropitant citrate monohydrate, nitroscanate, nitroxynil, oclacitinib maleate, oxfendazole, parvaquone, permethrin, phenazone, ponazuril, praziquantel, ractopamine HCL, rafoxanide, ricobendazole, r-praziquantel, sarolaner, s-methoprene, toldimfos sodium, toltrazuril, triclabendazole, xylazine base, xylazine HCl, and zilpaterol. It also provides anthelmintics, antiprotozoals, ectoparasiticides, phosphorus supplements, coccidiostats, and non-steroidal anti-inflammatory drugs. In addition, the company offers atovaquone, nitazoxanide, and praziquantel for anti malarial, anti diarrheal, and anthelmintic therapeutic categories. Further, it provides specialty chemicals, such as meglumine, n-ethyl-d-glucamine, n-octyl-d-glucamine, 1,4,7-trimethyl-1,4,7-triazonane, and Mn-MeTACN. It serves companies engages in manufacturing custom pharmaceuticals. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Rahul Jayant Nachane ACA, B. Com, DBF, MMS
Headquarters
Mumbai
Employees
498
Website
nglfinechem.comExchange
View on NSE ↗Key stats
Market cap
₹1,708.22 Cr
P/E ratio (TTM)
29.8
Dividend yield
0.06%
EPS (TTM)
₹92.73
Beta (1Y · daily vs NIFTY 50)
1.43
Beta (5Y · monthly vs NIFTY 50)
1.16
Shares float
16.77 L
EPS · quarter ended Jun 2026
₹29.78
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹257.98 Cr | ₹317.50 Cr | ₹278.08 Cr | ₹338.69 Cr | ₹363.03 Cr | ₹500.95 Cr | |
| EBITDA | ₹87.76 Cr | ₹78.53 Cr | ₹39.85 Cr | ₹67.40 Cr | ₹42.50 Cr | ₹87.42 Cr |
| ₹56.72 Cr | ₹49.90 Cr | ₹20.50 Cr | ₹41.32 Cr | ₹21.12 Cr | ₹48.13 Cr | |
| Diluted EPS | ₹91.81 | ₹80.77 | ₹33.18 | ₹66.88 | ₹34.19 | ₹77.9 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Pretax income, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹287.08 Cr | ₹355.54 Cr | ₹434.68 Cr | ₹545.50 Cr | |
| — | — | ₹32.50 Cr | ₹34.00 Cr | ₹77.66 Cr | ₹122.58 Cr | |
| Stockholders' equity | — | — | ₹222.55 Cr | ₹262.63 Cr | ₹282.43 Cr | ₹329.23 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹35.29 Cr | ₹20.47 Cr | ₹32.35 Cr | ₹43.32 Cr | |
| Investing cash flow | — | — | ₹-27.02 Cr | ₹-26.82 Cr | ₹-69.68 Cr | ₹-70.59 Cr |
| — | — | ₹-1.08 Cr | ₹-1.08 Cr | ₹37.47 Cr | ₹29.55 Cr | |
| Capital expenditure | — | — | ₹-31.41 Cr | ₹-28.52 Cr | ₹-74.29 Cr | ₹-89.85 Cr |
| End cash position | — | — | ₹7.83 Cr | ₹39.52 L | ₹53.45 L | ₹2.81 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | May 22–Dec 22(4Q) | Mar 23–Jun 23(2Q) | Sep 23–Dec 23(2Q) | Mar 24–Mar 26(9Q) | Jun 26 |
|---|---|---|---|---|---|
| Promoter | 73.81% | 73.53% | 73.06% | 72.74% | 72.49% |
| Public | 26.19% | 26.47% | 26.94% | 27.26% | 27.51% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| NGL Fine-Chem Limited | ₹1,668.07 Cr | ₹2,657.2 | 29.1 | 5.07 | 14.6% | 0.37 | +36.1% | +89.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.